Get started
Author

Scot Anthony Niglio

Observed names: S. Niglio, Scot A Niglio, Scot A. Niglio, Scot Niglio, Scott Niglio
Observed institutions: Rutgers, The State University of New Jersey, University of Central Florida, National Institutes of Health, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Johns Hopkins University, NYU Langone Health, National Cancer Institute, National Cancer Institute, Center for Cancer Research, Sidney Kimmel Comprehensive Cancer Center, Weill Cornell Medicine, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Rutgers Cancer Institute, Tisch Cancer Institute, New York University, Icahn School of Medicine at Mount Sinai
ORCID: 0000-0002-1421-1533
Observed ORCID: 0000-0002-1421-1533
OpenAlex ID: A5047686363
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
2024 · Andrea B. Apolo, Karla V. Ballman, et al. · New England Journal of Medicine · 168
PDF
Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
2020 · Andrea B. Apolo, Rosa Nadal, et al. · Journal of Clinical Oncology · 138
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial
2024 · Andrea Necchi, Mathieu Roumiguié, et al. · The Lancet Oncology · 99
Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis
2019 · Scot A. Niglio, Rachel Jia, et al. · European Urology · 77
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors
2023 · Talal El Zarif, Amin H Nassar, et al. · JNCI Journal of the National Cancer Institute · 59
PDF
Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer
2020 · Heather J. Chalfin, Tiziano Pramparo, et al. · Clinical Cancer Research · 40
PDF
Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach
2018 · Alessandro Laganà, Itai Beno, et al. · JCO Precision Oncology · 37
Clinical value of 18FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer
2021 · Ali Cahid Civelek, Scot A. Niglio, et al. · Urologic Oncology Seminars and Original Investigations · 29
Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors
2024 · Andrea B. Apolo, Daniel M. Girardi, et al. · Journal of Clinical Oncology · 28
PDF
Targeting Glutamatergic Signaling and the PI3 Kinase Pathway to Halt Melanoma Progression
2015 · Stephen A. Rosenberg, Scot A. Niglio, et al. · Translational Oncology · 26
PDF
Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial
2025 · Mansi Saxena, Jonathan F. Anker, et al. · Nature Cancer · 24
Early Mortality in Patients With Muscle-Invasive Bladder Cancer Undergoing Cystectomy in the United States
2018 · Kathryn E Marqueen, Nikhil Waingankar, et al. · JNCI Cancer Spectrum · 24
PDF
Effectiveness of Transurethral Resection plus Systemic Chemotherapy as Definitive Treatment for Muscle Invasive Bladder Cancer in Population Level Data
2018 · François Audenet, Nikhil Waingankar, et al. · The Journal of Urology · 22
Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers
2022 · Andrea B. Apolo, Pavlos Msaouel, et al. · American Society of Clinical Oncology Educational Book · 15
Interdigitating Dendritic Cell Sarcoma Presenting in the Skin: Diagnosis and the Role of Surgical Resection, Chemotherapy and Radiotherapy in Management
2014 · Stephen A. Rosenberg, Scot A. Niglio, et al. · Rare Tumors · 15
PDF
Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded Cohort
2025 · Viranda H. Jayalath, Melissa Assel, et al. · European Urology · 12
SMART: A phase II study of sacituzumab govitecan (SG) with or without atezolizumab immunotherapy in rare genitourinary (GU) tumors such as small cell, adenocarcinoma, and squamous cell bladder/urinary tract cancer, renal medullary carcinoma (RMC) and penile cancer.
2024 · Andre Rashad Kydd, Elias Chandran, et al. · Journal of Clinical Oncology · 11
Abstract CT084: A phase 1 study of LY4101174 (ETx-22), an antibody-drug conjugate targeting nectin-4, in patients with advanced or metastatic urothelial cancer and other solid tumors (trial in progress)
2024 · Jonathan Rosenberg, Renaud Sabatier, et al. · Cancer Research · 9
Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial.
2023 · Minas P. Economides, Matthew I. Milowsky, et al. · Journal of Clinical Oncology · 9
Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors.
2021 · Andrea B. Apolo, Daniel da Motta Girardi, et al. · Journal of Clinical Oncology · 9
A phase 2 study of sacituzumab govitecan with or without atezolizumab in rare genitourinary tumors (SMART) – design and rationale
2025 · Andre R. Kydd, Elias Chandran, et al. · Future Oncology · 7
Atezolizumab plus personalized neoantigen vaccination (PGV001) in patients with urothelial cancer.
2024 · Jonathan Forrest Anker, Mansi Saxena, et al. · Journal of Clinical Oncology · 5
PDF
Pd09-04 Interim Analysis of a Phase I Single-arm Study of the Combination of Durvalumab (medi4736) and Vicinium (oportuzumab Monatox, Vb4-845) in Subjects With High-grade Non-muscle-invasive Bladder Cancer Previously Treated With Bacillus Calmette-guerin (bcg) (nct03258593)
2021 · Sandeep Gurram, Sonia Bellfield, et al. · The Journal of Urology · 5
Small cell carcinoma of the bladder: Review of pathogenesis, presentation, and management
2025 · Nicholas I Simon, Andre R Kydd, et al. · Bladder Cancer · 4
E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors—design and rationale
2025 · Elias B. A. Chandran, Saad Atiq, et al. · Future Oncology · 4
Works count: 112
Citation count: 914
H-index: 15
I10-index: 17
Year
Topic
Type